Indian Experience with Adalimumab in Pediatric Rheumatology

Speciality: Pediatrics

Description:

A warm welcome to all the medical professionals in this interesting session on Indian Experience with Adalimumab in Pediatric Rheumatology
The use of Adalimumab in pediatric rheumatology in India has shown promising results, reflecting global experiences with this biologic agent. Adalimumab, a TNF-alpha inhibitor, has been increasingly utilized for treating various pediatric rheumatic conditions, such as juvenile idiopathic arthritis (JIA), where traditional therapies have proven insufficient. Indian clinical settings have reported significant improvements in disease activity, pain reduction, and overall quality of life in children treated with Adalimumab. The biologic has been instrumental in achieving better disease control and reducing the frequency of disease flares.
Despite its effectiveness, the use of Adalimumab in India presents challenges, particularly regarding accessibility and affordability. Biologics are often expensive, limiting their availability to a broader patient population. Additionally, there is a need for increased awareness and education among healthcare providers and families about the benefits and management of biologic therapies. Monitoring for potential side effects, such as infections, is also crucial, necessitating a robust follow-up system. Nevertheless, the integration of Adalimumab into pediatric rheumatology practice in India represents a significant advancement, offering hope for improved outcomes in young patients with severe rheumatic diseases.
Therefore, get an overall knowledge of indian experience with adalimuma

See More Webinars @ Hidoc Webinars